ABT-869 inhibits the growth of and prevents MOLM-13 tumor formation. (A) Daily oral administration of ABT-869 at concentrations of 5, 10, 20, and 40 mg/kg/day was initiated when the MOLM-13 tumors reached an average of 400 mm3 in volume (1 mouse per dosage group). The graph shows the dosage response to the inhibitor compared with tumors treated with vehicle control. (B). Mice injected with MOLM-13 cells were treated with 40 mg/kg/day ABT-869 or vehicle the day after injection of cells (2 mice per dosage group). The graph shows that the mice receiving treatment developed tumors after 26 days of treatment in contrast to the vehicle control (tumor size ± SEM). (C) ABT-869 prolongs survival in MV-4-11 bone engraftment model. NOD-SCID mice were injected with 5 × 106 MV-4-11 cells after bone marrow ablation with cyclophosphamide. Treatment with ABT-869 began on day 40 after injection and continued for another 20 weeks. Survival was determined by observation when the animal demonstrated hind limb paralysis or became moribund.
